Scirpusin A and B Composition for Anti-Obesity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for addressing obesity lack effective inhibitors of adipogenesis, particularly from natural sources, and existing extracts from Cyperus rotundus have not fully explored the anti-obesity potential of stilbenoid-derived compounds.

Innovation Solution

The composition comprising scirpusin A and scirpusin B, derived from the ethyl acetate fraction of Cyperus rotundus rhizomes, is used to inhibit adipogenesis and manage obesity through dietary supplementation, obtained via bioactivity-guided fractionation and characterized using LC-MS, HRMS, and NMR.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If hexane extract of Cyperus rotundus rhizomes is used, then anti-obesity properties are exhibited, but the active constituents are not stilbenoid-derived compounds

Engineering Contradiction:

Improveanti-obesity activityVSAvoididentity of active constituents

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent extracts and isolates stilbenoid-derived compounds (scirpusin A and scirpusin B) from the hexane extract of Cyperus rotundus rhizomes through systematic fractionation. This separates the active anti-obesity constituents from the bulk extract, identifying them as piceatannol dimers while maintaining their biological activity.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses ethyl acetate fractionation as an intermediary step between hexane extraction and final purification. This intermediate fractionation isolates the stilbenoid compounds from other constituents, enabling their identification as the active anti-obesity agents without losing their therapeutic effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Loss of information

If ethyl acetate fraction is used, then stilbenoid-derived compounds are identified, but anti-obesity activity is not previously reported

Engineering Contradiction:

Improveidentity of active constituentsVSAvoidanti-obesity activity

Core Design Contradiction:

Loss of informationVSReliability

Solution Approach 1:

The patent changes the chemical parameter focus from general phytochemicals to specifically stilbenoid-derived compounds through targeted fractionation and identification. By isolating scirpusin A and scirpusin B as piceatannol dimers, the patent establishes their anti-obesity activity where it was previously unreported, validating their therapeutic potential.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If piceatannol dimers scirpusin A and scirpusin B are isolated, then anti-adipogenic effect is enhanced, but complexity of isolation increases

Engineering Contradiction:

Improveanti-adipogenic effectVSAvoidisolation process

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the complex rhizome extract into distinct fractions based on solubility and chemical properties. By dividing the extraction process into hexane, ethyl acetate, and aqueous layers, followed by further fractionation of the ethyl acetate layer, the patent systematically isolates scirpusin A and scirpusin B from other constituents, enhancing anti-adipogenic effect while managing isolation complexity through structured segmentation.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS10172903B2Composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof

Publication Date: 2019.01.08 SAMI LABS LTD

AI summary

Disclosed are methods of managing hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of Cyperus rotundus rhizomes standardized to contain 5% of total stilbenes.